A Review of How Cannabinoids Could Help With Pain, Nausea, and Symptoms in Serious Illness
Cannabinoids showed promise for managing multiple symptoms in serious illness, including pain, appetite loss, nausea, and muscle spasm, potentially complementing opioid treatments.
Quick Facts
What This Study Found
This review examined the evidence for cannabinoid use in pain management and palliative care across several conditions.
The author described how the endocannabinoid system works alongside the opioid system as a retrograde neuromodulatory network. Clinical trial evidence suggested cannabinoid formulations could be useful for chronic pain, with delivery method and formulation playing critical roles in determining the risk-benefit profile.
A key theme was opioid-cannabinoid synergy: co-administration appeared to produce opioid-sparing effects, extend pain relief duration, and potentially reduce opioid tolerance and dependence. Beyond pain, cannabinoids addressed multiple symptoms simultaneously, including sleep disturbance, appetite loss, muscle spasm, and nausea.
The review also noted emerging evidence for anti-cancer and neuroprotective properties that could be particularly relevant in aging and terminally ill populations.
Key Numbers
The review covered clinical trials of synthetic and plant-based cannabinoids across multiple conditions, with a focus on pain, cancer, neurodegenerative disease, and HIV/AIDS symptom management.
How They Did This
This was a narrative review covering the mechanism of action of cannabinoids, marketed agents and those in clinical trials, and their therapeutic applications across chronic pain, cancer, neurodegenerative diseases, and HIV/AIDS.
Why This Research Matters
Palliative care patients often manage multiple symptoms with multiple medications. A single class of drugs that addresses pain, nausea, appetite, sleep, and muscle spasm simultaneously could reduce medication burden and improve quality of life in serious illness.
The Bigger Picture
The concept of cannabinoid-opioid synergy discussed in this review has gained significant traction. Several studies have since explored whether medical cannabis access reduces opioid use at population levels, with mixed but intriguing results.
What This Study Doesn't Tell Us
As a narrative review, it did not systematically grade the evidence. The clinical trial evidence available in 2007 was relatively limited. The review may have presented an optimistic perspective on cannabinoid therapy.
Questions This Raises
- ?Can cannabinoids meaningfully reduce opioid requirements in clinical practice?
- ?Which specific cannabinoid formulations and delivery methods optimize symptom relief while minimizing side effects?
Trust & Context
- Key Stat:
- Cannabinoid-opioid combination may extend pain relief and reduce opioid tolerance
- Evidence Grade:
- This is a narrative review drawing on clinical trials and preclinical evidence, providing a moderate overview but without systematic methodology.
- Study Age:
- Published in 2007. The cannabinoid-opioid interaction field has expanded significantly, and medical cannabis programs have proliferated since then.
- Original Title:
- Cannabinoids:their role in pain and palliation.
- Published In:
- Journal of pain & palliative care pharmacotherapy, 21(3), 19-28 (2007)
- Authors:
- McCarberg, Bill H
- Database ID:
- RTHC-00282
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids replace opioids for pain?
Based on the evidence reviewed, cannabinoids were presented as potential complements to opioids rather than replacements, with the combination possibly reducing the opioid dose needed. They may also address symptoms that opioids don't, like appetite loss.
What does "opioid-sparing" mean?
It means using cannabinoids alongside opioids might allow patients to achieve the same level of pain relief with a lower opioid dose, potentially reducing opioid side effects and dependence risk.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-cancer-pain-beyond-chemo-nausea
Cite This Study
https://rethinkthc.com/research/RTHC-00282APA
McCarberg, Bill H. (2007). Cannabinoids:their role in pain and palliation.. Journal of pain & palliative care pharmacotherapy, 21(3), 19-28.
MLA
McCarberg, Bill H. "Cannabinoids:their role in pain and palliation.." Journal of pain & palliative care pharmacotherapy, 2007.
RethinkTHC
RethinkTHC Research Database. "Cannabinoids:their role in pain and palliation." RTHC-00282. Retrieved from https://rethinkthc.com/research/mccarberg-2007-cannabinoidstheir-role-in-pain
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.